The funding was provided by o2h Ventures to back the University of Sussex spin out.
SB
Stingray Bio
Stingray Bio develops small molecule inhibitors to target the LMTK3 kinase signalling pathway in cancer treatment.
West Sussex, UK—Founded 2020
Stingray Bio is a spin out from the University of Sussex developing small molecule inhibitors for cancer treatment. The company focuses on targeting the LMTK3 kinase signalling pathway.
Filed accounts
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Current assets
Members only
Cash, assets and headcount from Stingray Bio's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Founders
GG
Georgios Giamas
Chief Scientific Advisor and Director
JS
John Spencer
Co-Founder
Investors
